MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference
January 05, 2023 06:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of innovative...
MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting
November 10, 2022 06:05 ET
|
MannKind
Technosphere® Insulin (TI) peaked 30 minutes faster and significantly reduced postprandial glucose excursions (PPGE) at 60 minutes compared to subcutaneous insulinsThe Afrezza with Basal Combination...
MannKind Corporation Reports 2022 Third Quarter Financial Results
November 08, 2022 08:00 ET
|
MannKind
3Q 2022 Total Revenues of $32.8 million; +48% vs. 3Q 20213Q 2022 Royalties from Tyvaso DPI of $6.2 million3Q 2022 Commercial Products Net Revenue of $16.3 million; +67% vs. 3Q 2021 DANBURY, Conn. and...
MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
November 01, 2022 06:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its...
MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference
September 21, 2022 17:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...
Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
September 06, 2022 06:15 ET
|
MannKind
Study supports the dosing regimen that will be pursued in further clinical programsNo serious adverse events or QT prolongation identifiedPlanning underway to discuss results and the ongoing clinical...
MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 01, 2022 06:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...
MannKind Corporation Reports 2022 Second Quarter Financial Results
August 09, 2022 16:00 ET
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) Tyvaso DPI™ approved by the FDA in May representing the second FDA-approved product using the Technosphere® inhalation platform V-Go® acquired May...
MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022
August 02, 2022 06:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 second quarter and year to date financial results and its...
MannKind Corporation to Participate in the BTIG Biotechnology Conference
August 01, 2022 06:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...